Psychedelic boom risks sidelining people of color despite new federal push and AbbVie's billion-dollar deal

The piece highlights that psychedelics are being praised for their therapeutic potential but still face scientific uncertainty and political debate.

President Trump signed an executive order aimed at accelerating regulatory pathways and expanding clinical trials for psychedelic treatments.

In parallel, AbbVie announced a billion-dollar acquisition of Bretisilocin, a psychedelic compound being developed for major depressive disorder, the first deal of its size in the sector.

The authors caution that racial minorities, who could stand to gain from these therapies, risk being excluded as the industry moves forward.